Angel News
Angel News
Angel News

Back to Homepage

8th November 2018

Medherant positive Phase I results for drug delivery patch

Mercia Technologies investment Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.

The TEPI Patch was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation. This marks the first clinical safety evaluation of Medherant’s novel adhesive, facilitating the development of the next generation of drug-in-adhesive patches.

...

Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage